Cíl studie: Posoudit vliv malnutrice u pacientů s karcinomem pankreatu (PC) na míru oxidačního stresu a na antioxidační systém organismu. Typ studie: Observační, strukturálně vyvážená studie případů a kontrol. Název a sídlo pracoviště: IV. Interní klinika, 1. LF UK a VFN v Praze, U Nemocnice 2, 128 01 Praha 2, Česká republika Materiál a metody: Do studie bylo zařazeno 68 pacientů (M/F = 36/32) s PC, kteří byli podle indexu NRI (nutrition risk index) rozděleni do dvou skupin na pacienty se středně těžkou až těžkou malnutricí (PC-MAL) a pacienty s lehkou malnutricí či bez malnutrice (PC-NOR). Každá skupina čítala 34 osob (M/F = 18/16) a mezi skupinami nebyl signifikantní rozdíl ve věku. Dále byla do studie zařazena na základě věku a pohlaví spárovaná kontrolní skupina (CON). Sledovaným subjektům byly odebírány vzorky po celonočním lačnění a kromě základních klinických a biochemických parametrů byly stanovovány markery oxidačního stresu (konjugované dieny v precipitovaných LDL; CD/LDL a oxidované LDL; ox-LDL/LDL), aktivity antioxidačních enzymů a koncentrace redukovaného glutathionu (GSH). Ke statistickému zpracování výsledků byl použit program STATISTICA (Stat Soft, CZ). Výsledky: Výsledky naší studie potvrzují zvýšený oxidační stres u pacientů s PC a to zvýšenými hladinami ox-LDL/LDL a CD/ LDL v porovnání s CON (p < 0,01). Signifikantně vyšší hladiny těchto markerů měli pacienti s malnutricí než bez malnutrice. Pozorovány byly rovněž výrazné změny v antioxidačním systému u pacientů s PC; kteří oproti CON skupině měli sníženou aktivitu katalázy (CAT, p < 0,01) glutationperoxidázy (p < 0,01), arylesterázovou (PON-A) i laktonázovou aktivitu (PON-L) paraoxonázy (p < 0,01) a koncentraci redukovaného glutathionu (p < 0,001) a zvýšené hladiny sérového amyloidu A (SAA, p < 0,001). Ovlivnění aktivit CAT, PON-A a PON-L a hladiny SAA bylo signifikantně větší u pacientů s podvýživou oproti PC pacientům bez příznaků malnutrice. Závěr: V této studii bylo prokázáno prohloubení oxidačního stresu a výraznější ovlivnění funkce antioxidačního systému organismu pacientů vlivem malnutrice.
Objective: To assess the influence of malnutrition in patients with pancreatic carcinoma (PC) on the oxidative stress and antioxidant system. Design: Observation, matched case-control study. Settings: This study was conducted at the 4th Department of Internal Medicine of General University Hospital in Prague, U Nemocnice 2, 128 01 Prague 2, Czech Republic Material and methods: In to our study 68 patients (M/F = 36/32) with PC were included and divided according to the nutrition risk index into two groups – patients with moderate or severe malnutrition (PC-MAL) and mild or no malnutrition (PCNOR). In both groups there were 34 patients (M/F = 18/16) with no difference in age between both groups. Furthermore, group of 34 sex- and age-matched healthy controls (CON) were enrolled into the study. The samplings were taken after overnight fast and apart from basic clinical and biochemical parameters markers of oxidative stress (level of conjugated dienes in precipitated LDL, CD/LDL and oxidized LDL, ox-LDL/LDL), activities of antioxidant enzymes and concentration of reduced glutathione (GSH) were assessed. For all statistical analysis the statistical program STATISTICA (Stat Soft, CZ) was used. Results: In our study we confirmed increased oxidative stress in PC, with higher levels of ox-LDL/LDL and CD/LDL compared to CON (p < 0.01). Significantly higher levels of these markers were in patients with malnutrition then without malnutrition. We observed also changes in antioxidant system of PC patients – these patients had decreased activity of catalase (CAT, p < 0.01), glutathione peroxidase (p < 0.01), arylesterase (PON-A) and also lactonase activity (PON-L) of paraoxonase (p < 0.01) and concentration of GSH (p < 0.001) and higher levels of serum amyloid A (SAA, p < 0.001). The changes in CAT, PON-A, PON-L and SAA levels were significantly higher in PC patients with malnutrition then without. Conclusion: In this study we proved the deepening of oxidative stress and the strongly impaired function of antioxidant system in PC patients due to malnutrition.
Chronický zánět prostaty může být příčinou symptomatické nebo komplikované benigní hyperplazie prostaty (BHP). Na základě dostupných dat má hexanový extrakt Serenoa repens (HESr) – CAPISTAN protizánětlivé vlastnosti. Cílem této studie bylo poskytnout nový pohled na protizánětlivé účinky HESr zkoumáním efektu na CPI (Chronic prostatic inflammation, chronický zánět prostaty) biomarkery u mužů s LUTS v důsledku BHP, využitím neinvazivních metod a zkoumáním souvislostí mezi hladinou biomarkerů a klinickými symptomy.
Chronic prostatic inflammation (CPI) can cause symptomatic or complicated benign prostatic hyperplasia (BPH). Based on available data, Capistan, a hexane extract of Serenoa repens (HESr), has anti-inflammatory properties. The aim of the present study was to provide a new insight into the anti-inflammatory effects of HESr by investigating the effect on CPI biomarkers in men with lower urinary tract symptoms (LUTS) due to BPH, while using non-invasive methods and exploring the association between the level of biomarkers and clinical symptoms.
- Keywords
- CAPISTAN, studie PERMIN,
- MeSH
- Urinalysis methods MeSH
- Anti-Inflammatory Agents * pharmacology therapeutic use MeSH
- Biomarkers urine MeSH
- Double-Blind Method MeSH
- Drug Evaluation MeSH
- Prostatic Hyperplasia * drug therapy MeSH
- Clinical Trials, Phase IV as Topic MeSH
- Middle Aged MeSH
- Humans MeSH
- Macrophage Inflammatory Proteins * analysis urine MeSH
- Specimen Handling methods MeSH
- Prostatitis * drug therapy MeSH
- Randomized Controlled Trials as Topic MeSH
- Plant Extracts pharmacology therapeutic use MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Serenoa * MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
Markers of oxidative stress and antioxidant status in relation to inflammatory mediators in septic patients (SPs) during the course of sepsis and after recovery were analysed. Patients were 30 critically ill adults in severe sepsis/septic shock, 19 of which completed 3 samplings (S1: within 24 h after onset of sepsis, S7: 7 days after S1, R7: 7 days after clinical recovery). Comparing SPs with healthy controls (HCs), enhanced C-reactive protein, procalcitonin, bilirubin and CuZn-superoxide dismutase activity were found at S1 only. Oxidized low-density lipoprotein, conjugated dienes and nitrotyrosine were increased at S1, culminated at S7 and reverted nearly to HC levels at R7. Reduced catalase activity and serum amyloid were observed at S1 and endured until R7. Increase in IL-6, IL-10 and tumour necrosis factor alpha (TNF-α) with accompanying decrease in apolipoprotein A1, high-density lipoprotein (HDL) cholesterol, selenium, zinc, albumin, paraoxonase 1 and glutathione peroxidase 1 activity appeared at S1 and persisted until R7. TNF-α, IL-10 and markers of oxidative stress were in negative correlation with HDL cholesterol and albumin at R7. After clinical recovery, increased cytokines and decreased antioxidants were accompanied by lower albumin and HDL cholesterol levels. During this important and beneficial period of tissue repair, patients with prolonged persistence of this status are probably more vulnerable to secondary infections and should be dealt with as constituting a high-risk population.
- MeSH
- Cytokines blood MeSH
- Cholesterol, HDL blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Oxidative Stress MeSH
- Prospective Studies MeSH
- Aged MeSH
- Sepsis immunology metabolism MeSH
- Serum Albumin metabolism MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Benigní hyperplazie prostaty je nejčastější benigní onemocnění mužů, jehož prevalence a incidence s věkem stoupá. Charakterizuje ji zvětšení prostaty, které svými důsledky může významně ovlivnit kvalitu pacientova života. V posledních letech se klinicky benigní hyperplazie prostaty řadí mezi širší skupinu diagnóz označovaných jako LUTS (lower urinary tract symptoms). Pohled na problematiku a léčbu LUTS se řídí doporučenými postupy Evropské urologické společnosti. V posledních letech zaznamenala léčba tohoto onemocnění značný rozvoj od pouhého sledování přes farmakoterapii až po možnosti chirurgické.
Benign prostatic hyperplasia is the most common benign disease in men, the prevalence and incidence of which increases with age. It is characterized by enlargement of the prostate. The consequences of the enlarged prostate may significantly affect the patient's quality of life. Recently, BHP has been clinically classified under a wider group of diagnoses called LUTS (Lower Urinary Tract Symptoms). The treatment of LUTS follows recommended procedures of the European Association of Urology. In recent years, the treatment of this disease is marked by a considerable development from merely examining the case through pharmacotherapy to surgical options.
- MeSH
- Adrenergic alpha-Antagonists therapeutic use MeSH
- Muscarinic Antagonists pharmacology contraindications therapeutic use MeSH
- Prostatic Hyperplasia * diagnostic imaging drug therapy surgery MeSH
- Humans MeSH
- Lower Urinary Tract Symptoms diagnosis etiology MeSH
- Transurethral Resection of Prostate methods MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- MeSH
- Algorithms MeSH
- Diagnosis, Differential MeSH
- Humans MeSH
- Eye Diseases * diagnosis MeSH
- Check Tag
- Humans MeSH
- Keywords
- paraoxonáza, snížená aktivita paraoxonázy, koncentrace sérového amyloidu A, zvýšená hladina koncentrace amyloidu A,
- MeSH
- Aryldialkylphosphatase * analysis pharmacology physiology blood metabolism MeSH
- Blood Chemical Analysis * MeSH
- Adult MeSH
- Carcinoma, Ductal, Breast * diagnosis physiopathology MeSH
- Carcinoma, Pancreatic Ductal * diagnosis physiopathology MeSH
- Clinical Chemistry Tests * MeSH
- Clinical Laboratory Techniques * MeSH
- Clinical Trials as Topic methods statistics & numerical data MeSH
- Humans MeSH
- Serum Amyloid A Protein * analysis pharmacology physiology metabolism MeSH
- Inflammation * diagnosis MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
